• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck: Secondary Analysis of a Phase 2 Clinical Trial.新辅助西米普利单抗治疗晚期可切除头颈部皮肤鳞状细胞癌患者的疗效：一项2期临床试验的二次分析
JAMA Otolaryngol Head Neck Surg. 2023 Sep 1;149(9):847-849. doi: 10.1001/jamaoto.2023.1729.
2
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.头颈部局部晚期可切除皮肤鳞状细胞癌新辅助免疫治疗的 II 期临床试验。
Clin Cancer Res. 2021 Aug 15;27(16):4557-4565. doi: 10.1158/1078-0432.CCR-21-0585. Epub 2021 Jun 29.
3
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study.新辅助西妥昔单抗联合手术治疗 II-IV 期皮肤鳞状细胞癌：一项单臂、多中心、Ⅱ期研究的随访和生存结果。
Lancet Oncol. 2023 Nov;24(11):1196-1205. doi: 10.1016/S1470-2045(23)00459-X. Epub 2023 Oct 21.
4
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.新辅助西妥昔单抗治疗 II 期至 IV 期皮肤鳞状细胞癌。
N Engl J Med. 2022 Oct 27;387(17):1557-1568. doi: 10.1056/NEJMoa2209813. Epub 2022 Sep 12.
5
Favorable efficacy of S-1 treatment for locoregionally advanced cutaneous squamous cell carcinoma in the head and neck region.S-1 治疗头颈部局部晚期皮肤鳞状细胞癌的疗效良好。
J Dermatol. 2024 Feb;51(2):271-279. doi: 10.1111/1346-8138.17057. Epub 2023 Nov 27.
6
Management of locoregional recurrence in cutaneous squamous cell carcinoma of the head and neck.头颈部皮肤鳞状细胞癌局部区域复发的管理
Eur Arch Otorhinolaryngol. 2017 Jan;274(1):501-506. doi: 10.1007/s00405-016-4243-7. Epub 2016 Aug 6.
7
Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial.卡瑞利珠单抗联合白蛋白结合型紫杉醇和顺铂用于可切除局部晚期头颈部鳞状细胞癌的新辅助化疗免疫治疗：一项II期试点试验
Nat Commun. 2024 Mar 11;15(1):2177. doi: 10.1038/s41467-024-46444-z.
8
Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck.头颈部晚期皮肤鳞状细胞癌患者的细胞毒性和靶向全身治疗。
Head Neck. 2021 May;43(5):1592-1603. doi: 10.1002/hed.26626. Epub 2021 Feb 1.
9
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.CheckMate 358 试验中可切除的 HPV 阳性和 HPV 阴性头颈部鳞状细胞癌患者的新辅助纳武利尤单抗治疗。
J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2021-002568.
10
Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial.新辅助化疗免疫治疗局部晚期头颈部鳞状细胞癌：单臂 2 期临床试验。
Clin Cancer Res. 2022 Aug 2;28(15):3268-3276. doi: 10.1158/1078-0432.CCR-22-0666.

引用本文的文献

1
Efficacy of Neoadjuvant Cemiplimab Treatment for Cutaneous Squamous Cell Carcinoma-A Systematic Review.新辅助西米普利单抗治疗皮肤鳞状细胞癌的疗效——一项系统评价
Int J Mol Sci. 2025 Aug 21;26(16):8109. doi: 10.3390/ijms26168109.
2
Impact of Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma.辅助性西米普利单抗在高危皮肤鳞状细胞癌中的作用
Curr Oncol. 2025 Aug 15;32(8):459. doi: 10.3390/curroncol32080459.
3
Top advances of the year: Developments of immunotherapy in cutaneous squamous cell carcinoma, 2023-2024.年度重大进展：2023 - 2024年皮肤鳞状细胞癌免疫治疗的进展
Cancer. 2025 Jun 1;131(11):e35920. doi: 10.1002/cncr.35920.
4
Neoadjuvant Immunotherapy in Cutaneous Squamous Cell Carcinoma: Systematic Literature Review and State of the Art.皮肤鳞状细胞癌的新辅助免疫疗法：系统文献综述与现状
Cancers (Basel). 2025 Feb 14;17(4):637. doi: 10.3390/cancers17040637.
5
Neoadjuvant Approaches to Non-Melanoma Skin Cancer.非黑色素瘤皮肤癌的新辅助治疗方法
Cancers (Basel). 2023 Nov 21;15(23):5494. doi: 10.3390/cancers15235494.

Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck: Secondary Analysis of a Phase 2 Clinical Trial.

作者信息

Ferrarotto Renata, Nagarajan Priyadharsini, Maronge Jacob M, Johnson Jason M, Rosenthal David I, Myers Jeffrey N, Gross Neil D

机构信息

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston.

出版信息

JAMA Otolaryngol Head Neck Surg. 2023 Sep 1;149(9):847-849. doi: 10.1001/jamaoto.2023.1729.

DOI:10.1001/jamaoto.2023.1729
PMID:37535378
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10401391/
Abstract
摘要